Announcement of an Exempt Purchase

Prismasol is for continuous renal replacement therapy (CRRT) is a common modality for management of acute renal failure in critically ill patients. This therapy provides slow removal of fluids and solutes intended to substitute for impaired renal function over an extended period of time.

This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Prismasol renal replacement solution is indicated for use as replacement solution in Continuous Renal Replacement Therapy to replace plasma volumed removed by ultrafiltration and to correct electrolyte and acid-base imbalances in critially ill patients. This is a common modality for patients in acute renal failure which provides slow removal of fluids and solutes intended to substitute for impaired kidney function.